Výsledky vyhledávání - "Serologic and Safety Studies of a Group a Meningococcal Conjugate Vaccine"

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination

Autor: Brian D. Plikaytis, Olubukola T. Idoko, Ray Borrow, Helen Findlow, Marie-Pierre Preziosi, Daniel Holme, George M. Carlone, Samba O. Sow

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Sub-Saharan Africa has experienced epidemic cycles of Neisseria meningitidis group A (MenA) disease approximately every 5–10 years, with high disease incidence. One of the worst epidemics occurred in 1996, with greater than 250 000 recorded cases a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc951c91b6a7d8028ce97b9700e74462
https://doi.org/10.1093/cid/civ505

Zobrazit plný text záznamu

MenAfriVac as an Antitetanus Vaccine

Autor: Yuxiao Tang, F. Marc LaForce, Ahmadu Yakubu, Prasad S. Kulkarni, Ray Borrow

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Maternal and neonatal tetanus is still a significant, although vaccine-preventable, cause of morbidity and mortality in many developing countries. When tetanus develops, case-fatality rates are high and treatment is often limited by paucity of resour

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed56327c855a45c81f0b40e69a718e1
https://doi.org/10.1093/cid/civ512

Zobrazit plný text záznamu

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali

Autor: Christian Meier, Samba O. Sow, Panchali Roy Chowdhury, Abraham Hodgson, Prasad S. Kulkarni, Godwin Enwere, Brian D. Plikaytis, Hewad Laraway, Marie-Pierre Preziosi, Matthias Niedrig, Yuxiao Tang

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new menin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b227078c555d9c9eefc37cc619e905
https://doi.org/10.1093/cid/civ603

Zobrazit plný text záznamu

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali

Autor: Kelly Townsend, Ray Borrow, Awa Traoré Eps Dembélé, Xilian Bai, Samba O. Sow, Uma Onwuchekwa, Nicole E. Basta, Helen Findlow, Abdoulaye Berthe, Rahamatou Moustapha Boukary, Lesley Mabey

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Efforts to prevent the large-scale outbreaks of meningococcal disease that have led to significant morbidity and mortality in the African meningitis belt, a region stretching from Senegal to Ethiopia, changed dramatically in 2010 when a newly develop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::667a98fddb0e5def127ae21a4aa38c1e
https://doi.org/10.1093/cid/civ602

Zobrazit plný text záznamu

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3c9bd3e3900cd1e557a67bff078efc
http://europepmc.org/articles/PMC4639491

Zobrazit plný text záznamu

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac

Autor: Brian D. Plikaytis, Yuxiao Tang, Marie-Pierre Preziosi, Ray Borrow

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background. A meningococcal group A conjugate vaccine, PsA-TT (MenAfriVac), developed through the Meningitis Vaccine Project and manufactured by the Serum Institute of India, Ltd, was tested in multiple clinical trials conducted mainly in Africa. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a3b62a7d3f8ba7f8addb98a6846a45
http://europepmc.org/articles/PMC4639503

Zobrazit plný text záznamu

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

The “meningitis belt” of sub-Saharan Africa runs across the continent from Senegal to Ethiopia, and this region is prone to major epidemics of meningococcal meningitis, with a high case fatality rate and serious sequelae. Until recently, most epi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d44d26a1e8cb845e6ead95ad38195a

Zobrazit plný text záznamu

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Autor: Caroline Trotter, Andromachi Karachaliou, Andrew J. K. Conlan, Marie-Pierre Preziosi

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

The African meningitis belt suffers from frequent large epidemics of meningococcal meningitis. A novel vaccine against Neisseria meningitidis group A (MenA), the major cause of epidemic meningitis, was developed through the Meningitis Vaccine Project

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eddaa69fcb3e90de7ddc560950de91f
https://www.repository.cam.ac.uk/handle/1810/248770

Zobrazit plný text záznamu

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso

Autor: Bradford D. Gessner, Seydou Yaro, Berthe-Marie Njanpop Lafourcade, Hervé Kpoda, Caroline Trotter, Ray Borrow, Ikenna Nwakamma, Judith E. Mueller, Catherine Martin, Haoua Tall, Helen Findlow, Xilian Bai, Jean-Bosco Ouédraogo, Soumeya Ouangraoua

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases
Clinical Infectious Diseases, 2015, 61 (suppl_5), pp.S540-S546. ⟨10.1093/cid/civ519⟩
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S540-S546. ⟨10.1093/cid/civ519⟩

International audience; BACKGROUND:A group A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriVac), was introduced in Burkina Faso via mass campaigns between September and December 2010, targeting the 1- to 29-year-old population. This study de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d13ad1207151b9cc2b9b0cbebb56f498
https://pubmed.ncbi.nlm.nih.gov/26553686

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání